# Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/antiangiogenic-therapy-using-bevacizumab-in-recurrent-high-grade-glioma-impact/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Ashwatha Narayana,Patrick D. Kelly,John G. Golfinos,Erik Parker,Glyn Johnson,Edmond A. Knopp,David Zagzag,Ingeborg Fischer,Shahzad Raza,Praveen Medabalmi,Patricia Eagan,Michael L. Gruber |
| Citations | 245 |
| DOI | 10.3171/2008.4.17492 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2130139391 |
| PMID | 18834263 |
| Type | article |
| Year | 2008 |

## Paper authors

- [John G. Golfinos](https://scholariq.org/researchers/john-g-golfinos/)

## Paper journal

- [Journal of neurosurgery](https://scholariq.org/journals/journal-of-neurosurgery/)

## Paper primary topic

- [Glioma Diagnosis and Treatment](https://scholariq.org/topics/glioma-diagnosis-and-treatment/)

## Paper topics

- [Glioma Diagnosis and Treatment](https://scholariq.org/topics/glioma-diagnosis-and-treatment/)
- [Angiogenesis and VEGF in Cancer](https://scholariq.org/topics/angiogenesis-and-vegf-in-cancer/)
- [Brain Metastases and Treatment](https://scholariq.org/topics/brain-metastases-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.